Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Deferred Taxes (2020 - 2025)

Historic Deferred Taxes for Catalyst Pharmaceuticals (CPRX) over the last 6 years, with Q3 2025 value amounting to -$2.4 million.

  • Catalyst Pharmaceuticals' Deferred Taxes fell 12815.7% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$217000.0, marking a year-over-year decrease of 10196.2%. This contributed to the annual value of $9.4 million for FY2024, which is 4731.17% down from last year.
  • According to the latest figures from Q3 2025, Catalyst Pharmaceuticals' Deferred Taxes is -$2.4 million, which was down 12815.7% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Deferred Taxes registered a high of $13.9 million during Q3 2023, and its lowest value of -$2.7 million during Q4 2021.
  • Its 5-year average for Deferred Taxes is $804789.5, with a median of -$883000.0 in 2023.
  • Its Deferred Taxes has fluctuated over the past 5 years, first plummeted by 26902.71% in 2021, then surged by 159282.66% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Deferred Taxes (Quarter) stood at -$2.7 million in 2021, then skyrocketed by 53.19% to -$1.3 million in 2022, then surged by 31.28% to -$883000.0 in 2023, then tumbled by 189.35% to -$2.6 million in 2024, then grew by 5.4% to -$2.4 million in 2025.
  • Its Deferred Taxes was -$2.4 million in Q3 2025, compared to $2.4 million in Q2 2025 and $2.3 million in Q1 2025.